

DKSH & LEO Pharma to extend dermatology, thrombosis solutions in Asia

29 September 2022 | News

Extends partnership to serve across Hong Kong, Malaysia, Singapore, Taiwan, Thailand, Vietnam, and the Philippines



DKSH Business Unit Healthcare, a leading partner for healthcare companies seeking to grow their business in Asia and beyond, has partnered with Denmark-headquartered LEO Pharma to bring high-quality therapeutic products for dermatology and thrombosis to patients across Asia.

The two companies are partnering in Hong Kong, Malaysia, Singapore, Taiwan, Thailand, Vietnam, and the Philippines to build a strong brand presence, increase market share, and ultimately improve patient outcomes.

In Asia, DKSH will support LEO Pharma by building dedicated sales and marketing teams and managing logistics and product distribution. Through its modern trade, traditional trade, hospitals, clinics, and other medical channels, LEO Pharma aims to reach patients throughout the region. LEO Pharma also offers a wide range of innovative treatments and therapies for all skin disease severities as well as thrombosis.

Bijay Singh, Head of Business Unit Healthcare at DKSH, said: “we strive to help patients in Asia to have better access to high-quality and innovative products and solutions. While we drive their growth across the region, LEO Pharma can focus on researching and developing products and solutions for people with skin conditions.”

Image Caption: Khalid Aouidat, Vice President, Commercial Activities, SEA, LEO Pharma (left) and Bijay Singh, Head of Business Unit Healthcare at DKSH (right) at LEO Pharma's head office in Denmark.